EP Patent

EP2676660A1 — Compositions preventing hypertension comprising soluplus

Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2013-12-25 · 12y expired

What this patent protects

The invention is related to a pharmaceutical composition, characterized in that; it comprises angiotensin II receptor antagonist or a pharmaceutically acceptable salt or ester or racemic mixture thereof with polyvinyl caprolactam- polyvinyl acetate-polyethylene glycol graft copol…

USPTO Abstract

The invention is related to a pharmaceutical composition, characterized in that; it comprises angiotensin II receptor antagonist or a pharmaceutically acceptable salt or ester or racemic mixture thereof with polyvinyl caprolactam- polyvinyl acetate-polyethylene glycol graft copolymer.

Drugs covered by this patent

Patent Metadata

Patent number
EP2676660A1
Jurisdiction
EP
Classification
—
Expires
2013-12-25
Drug substance claim
No
Drug product claim
No
Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.